The erythropoietin-mediated neuroprotective effects have been reported in diverse studies of ischemia, parkinsonism, brain trauma, seizures and epilepsy [253,254,255,256,257,258,259,260,261,262], as well as its therapeutic effects, in different neurological disorders, such as stroke [263], schizophrenia [264] and Parkinson’s disease [265], among others. This evidence concerns the gene EPO and Parkinson disease.